The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched ...

By the time someone reached me, they had often been on a diagnostic journey for years – misdiagnosed, undertreated, cycling ...

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

The Federal Trade Commission (FTC) and several US states have accused Martin Shkreli of violating a lifetime restraining ...

Radiopharmaceuticals are a rapidly advancing class of radioactive compounds with diagnostic and therapeutic applications. In this article, we focus on the supply chain and how players, current and ...

Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result in an early breast cancer trial, building on earlier data in more advanced ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency and CNS tropism, that lie at the core of developing new antisense and RNA ...